Although antibodies are part of the treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancers, no active forms of immunotherapy such as immune checkpoint inhibitors are currently approved for breast cancer. Here, ERBB2 is linked to breast carcinoma.